ALLR News and Press, Allarity Therapeutics Inc.

         Extends Company Cash Runway into Mid-2028 Financing Expected to Fund Completion of Phase 2 Ovarian Cancer Trial Financing Supports Acceleration Toward Pivotal Trial and Commercialization Financing Structured as Non-Convertible D...

     Stenoparib is being evaluated in combination with temozolomide clinical benefit in relapsed Small Cell Lung Cancer Trial is fully funded by the U.S. Department of Veterans Affairs and is open for enrollment at 11 VA sites nationwide Relapsed SCLC remains an are...

         This is the first trial combining Allarity’s stenoparib with another anti-cancer agent Stenoparib’s favorable safety profile supports potential for use in combination regimens Trial is fully funded by the U.S. Departm...

TARPON SPRINGS, Fla.,  December 31, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathw...

2025-11-14 13:34:16 ET More on Allarity Therapeutics Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information for Allarity Therapeutics Read the full article on Seeking Alpha ...

Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months in ongoing Phase 2 trial Advanced DRP ® platform through new licensing agreement TARPON SPRINGS, F...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

2025-09-25 17:46:33 ET More on Allarity Therapeutics Seeking Alpha’s Quant Rating on Allarity Therapeutics Historical earnings data for Allarity Therapeutics Financial information for Allarity Therapeutics Read the full article on Seeking Alpha ...

- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian Cancer Patients receiving stenoparib/2X-121 twice daily - Two patients continue on therapy now more than 24 months - Clinical Benefit Ev...

TARPON SPRINGS, Fla., September 17, 2025 – Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor...